TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07643766: A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Sponsor: Enveda Therapeutics · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 200 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$309,600

Rescue Site Savings

+$206,400

Unlock Full NCT07643766 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07643766 Rescue Dossier →